Zubsolv® (buprenorphine and naloxone) sublingual tablet (CIII) is indicated
for the maintenance treatment of opioid dependence and should be used as part of
a comprehensive treatment plan, which includes counseling and psychosocial
Abstral is a drug that provides fast and effective treatment of breakthrough
pain in cancer patients. It is based on Orexo's sublingual tablet technology and
the analgesic fentanyl.
Edluar is based on Orexo’s sublingual tablet technology and the active
substance zolpidem and offers treatment for short-term insomnia. Zolpidem is a
well-documented substance that has been used for a long time against insomnia.
The Edluar tablet is placed under the tongue where it rapidly dissolves and the
active substance is absorbed through the mucous membrane.
Orexo previously marketed Diabact® UBT, Heliprobe® System and
IRIS™ through its subsidiary Kibion. These tests and analytical instruments
are used in breath tests to diagnose the gastric ulcer bacterium
Helicobacter pylori. Kibion was divested as of April 30, 2015. Read
more in the press release.